Alzheimer' Disease
Conditions
Keywords
Alzheimer's disease, fmri, face recognition, rivastigmine
Brief summary
The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.
Interventions
DRUGrivastigmine
Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
Sponsors
Kuopio University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Probable Alzheimer's disease according to the NINCDS-ADRDA criteria * mild disease, CDR 1 * the clinician is planning to start anticholinesterase treatment
Exclusion criteria
* cognitive impairment for other reason than Alzheimer's disease * severe depression * other unstable physical disease * medal in body prevention MRI examination, claustrophobia * cardiac pacemaker * other significant neurologic or psychiatric disease * contraindication for anticholinesterase treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FMRI response in face recognition task | at baseline and at 1 mo |
Secondary
| Measure | Time frame |
|---|---|
| treatment response measured by ADAS-cog | at 6 month and 1 year |
Countries
Finland
Outcome results
None listed